^
    Back
    Association details:
    Biomarker:KIT positive
    Cancer:Gastrointestinal Stromal Tumor
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST)….the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment...
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet
    Title:

    Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

    Published date:
    03/28/2009
    Excerpt:
    Eligible patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry....Imatinib significantly improved recurrence-free survival compared with placebo (98% [95% CI 96–100] vs 83% [78–88] at 1 year; hazard ratio [HR] 0·35 [0·22–0·53]; one-sided p<0·0001).
    DOI:
    10.1016/S0140-6736(09)60500-6
    Trial ID:
    NCT00041197
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

    Excerpt:
    ...Histologically confirmed soft tissue sarcoma Malignant fibrous histiocytoma Liposarcoma Rhabdomyosarcoma Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma Angiosarcoma Hemangiopericytoma Neurogenic sarcoma Unclassified sarcoma Miscellaneous sarcoma (including mixed mesodermal tumors of the uterus) Gastrointestinal stromal tumor (GIST) (must be c-kit positive)...
    Trial ID:
    NCT00006357
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor

    Excerpt:
    ...- Tumor must stain positive for c-Kit (CD117) or platelet-derived growth factor receptor-alpha (PDGFRA) by immunohistochemistry...
    Trial ID:
    NCT00112632
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Jejunoileal vs Gastric GIST in the Era of Imatinib.

    Excerpt:
    ...Number of patients with a molecular analysis positive for KIT mutation`KIT Gene mutation`Number of patients with a molecular analysis positive for PDGFRA mutation`PDGFRA Gene mutation`Number of patients with immunohistochemical expression of CD117`Expression of CD117`Number of patients with immunohistochemical expression of DOG1`Expression of DOG1`Number of patients with recurrence after treatment with tyrosinkin inhibitors.`...
    Trial ID:
    NCT03923400
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

    Excerpt:
    ...- Tumor must stain positive for c-Kit (CD117) and/or discovered on gist-1 (DOG-1) by immunohistochemistry...
    Trial ID:
    ZJGIST-01
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Ipilimumab and Imatinib Mesylate in Advanced Cancer

    Excerpt:
    ...For expansion cohorts, patients must have metastatic or unresectable gastrointestinal stromal tumor (GIST), melanoma, or uncategorized tumors with tumor biopsies that are positive for c-KIT mutations by polymerase chain reaction (PCR) or immunohistochemistry (IHC)....
    Trial ID:
    NCT01738139
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

    Excerpt:
    ...- Tumor must stain positive for Kit (CD117) by polyclonal DAKO antibody staining...
    Trial ID:
    NCT00103168
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

    Excerpt:
    ...- Metastatic and/or locally advanced GIST, with diagnosis based on histology with positive c-kit and/or DOG-1, or with a GIST-typical mutation in KIT or PDGFR...
    Trial ID:
    PAGIST
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Gan To Kagaku Ryoho
    Title:

    [Preoperative Imatinib Therapy Followed by Laparoscopic Local Gastrectomy for a Giant Gastric Gastrointestinal Stromal Tumor-A Case Report]

    Excerpt:
    A 55-year-old man complained of abdominal distention. Gastroscopy showed a submucosal tumor in the upper-third portion of the stomach, with a biopsy diagnosis of gastrointestinal stromal tumor(GIST)…A pathological diagnosis was c-kit-positive GIST, with less than 5/50 HPF of mitotic counts. Imatinib was restarted 2 weeks after the operation. The patient is alive 8 months after the operation, with no obvious recurrence. Preoperative imatinib therapy can be a useful option for large GIST tumors.